IGF1 and acromegaly: With this aim we examined the evolution of clinical parameters, GH/IGF-1 secretion and tumour mass after a very long-term drug discontinuation in a series of selected patients with acromegaly characterized by an optimal disease control during chronic treatment with different long-acting SAs.